Skip to main content

Ery

Generic: Erythromycin

Verified·Apr 23, 2026
Manufacturer
Padagis
NDC
80005-155
RxCUI
797452
Route
TOPICAL
ICD-10 indication
L70.0

Affordability Check

How much will you actually pay for Ery?

In 30 seconds, see every legitimate way to afford Ery — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Ery

What is this medication? Ery is a prescription antibiotic medication primarily used for the topical treatment of acne vulgaris. It contains the active ingredient erythromycin, which belongs to a group of medicines known as macrolide antibiotics. This medication works by inhibiting the growth of bacteria that contribute to the development of acne, such as Cutibacterium acnes. By reducing the number of bacteria on the skin and lowering inflammation, it helps to clear existing pimples and prevent new breakouts from forming. This medication is typically available as a topical solution or saturated pads that are applied directly to the affected areas of the skin. It is often prescribed as part of a broader skin care regimen and may be used in combination with other acne treatments to improve overall results. While generally well-tolerated, some users may experience mild side effects such as skin dryness, redness, or a slight stinging sensation. It is important to follow the specific instructions provided by a healthcare professional to ensure the medication is used safely and effectively.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Ery. Official source: DailyMed (NLM) · Label effective Oct 11, 2024

Indications and usage
INDICATIONS AND USAGE Erythromycin Topical Solution USP, 2% is indicated for the topical treatment of acne vulgaris.
Dosage and administration
DOSAGE AND ADMINISTRATION Erythromycin Topical Solution USP, 2% should be applied over the affected areas twice a day (morning and evening) after the skin is thoroughly washed with warm water and soap and patted dry. Acne lesions on the face, neck, shoulders, chest, and back may be treated in this manner. This medication should be applied with applicator top. If fingertips are used, wash hands after application. Drying and peeling may be controlled by reducing the frequency of applications.
Contraindications
CONTRAINDICATIONS Erythromycin Topical Solution USP, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.
Warnings
WARNINGS Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”. After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.
Adverse reactions
ADVERSE REACTIONS The following local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness of the skin have also been reported with topical use of erythromycin. Generalized urticarial reactions possibly related to the use of erythromycin, which required systemic steroid therapy have been reported.
Use in pregnancy
Pregnancy: Teratogenic Effects: Pregnancy Category B - There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Ery appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-07-31).

Covered by plans

67%

3,661 of 5,490 plans

Most common tier

Tier 3

On 36% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)52
23%
Tier 2 (generic)61
27%
Tier 3 (preferred brand)82
36%
Tier 4 (non-preferred brand)34
15%

Step therapy: 0% of formularies

Quantity limits: 42% of formularies

Coverage breadth: 229 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.

Rare-disease navigation (specialists, trials, patient communities)

Ery treats a rare condition. For in-depth disease pages on our sister site:

UniteRare.org is our sister site for rare-disease navigation — same editorial team, same accuracy standards.